EUVIMEDEUVIMED entdecken
Crossref

Tofacitinib for severe alopecia areata: experience from a university tertiary hospital

Patrícia Amoedo, Pedro Rolo Matos, Alberto Mota, Ana Filipa Pedrosa

European Journal of Dermatology · 2024

DOI: 10.1684/ejd.2024.4614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2024. Verfasst von Patrícia Amoedo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Dermatologia e Venereologia do Centro Hospitalar Universitário de São João, Porto, Portugal. Hauptthemen laut MEDLINE: Alopecia Areata, Piperidines, Pyrimidines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BackgroundPrevious studies indicate that a postbiotic extract from Aquaphilus dolomiae (ADE-G3) improves skin barrier function and relieves neuroinflammation.ObjectivesEvaluation of an ADE-G3-based soothing cream for managing sensitive facial skin.Materials & MethodsThis real-world, international, pre-post comparative study involved adults with sensitive facial skin who used the study product once or twice daily for two to three months according to usual practice. Subjects reported changes in perceived clinical symptoms using self-administered questionnaires. Physicians assessed changes in xerosis severity, overall product effectiveness and tolerability. User satisfaction and quality of life (QoL) assessments, and subgroup analyses according to the factors triggering sensitive skin were also conducted.ResultsIn total, 2,382 subjects with sensitive facial skin (female: 79%; median age: 40 years) were included. An immediate skin soothing effect after the first ADE-G3-based cream application was reported by 93% of subjects, and improvements in symptoms were reported in 94% after a mean of nine days of product use. After several months of use (mean: 71±21 days), xerosis severity and dermatological-related QoL significantly improved in the whole study population and in the subgroups (pConclusionRegular use of the ADE-G3-based cream was shown to be effective in real-world management of sensitive facial skin, regardless of the factors involved in triggering skin sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataPiperidinesPyrimidinesHumansTertiary Care CentersUniversitiesAlopecia

Substanzen

tofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Serviço de Dermatologia e Venereologia do Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Serviço de Dermatologia e Venereologia do Centro Hospitalar Universitário de São João, Porto, Portugal, Facudade de Medicina da Universidade do Porto e CINTESIS, Portugal.

Zitieren

APA

Amoedo, P., Matos, P. R., Mota, A., & Pedrosa, A. F. (2024). Tofacitinib for severe alopecia areata: experience from a university tertiary hospital. European Journal of Dermatology. https://doi.org/10.1684/ejd.2024.4614

Vancouver

Amoedo P, Matos PR, Mota A, Pedrosa AF. Tofacitinib for severe alopecia areata: experience from a university tertiary hospital. European Journal of Dermatology. 2024. doi:10.1684/ejd.2024.4614

BibTeX
@article{Amoedo2024,
  author = {Amoedo, Patrícia and Matos, Pedro Rolo and Mota, Alberto and Pedrosa, Ana Filipa},
  title = {Tofacitinib for severe alopecia areata: experience from a university tertiary hospital},
  journal = {European Journal of Dermatology},
  year = {2024},
  doi = {10.1684/ejd.2024.4614}
}
Kostenlos starten →